Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Cancer therapy

Boosting CAR T cells with anti-tumor mRNA vaccines

Nature Medicine volume 29, pages 2711–2712 (2023)Cite this article

A new approach that combines CAR T cells with serial mRNA vaccine injections facilitates robust anti-neoplastic activity in patients with genitourinary cancers, which will pave the way for a promising new targeted treatment strategy.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: CAR T cell–CARVac therapy in CLDN6+ solid tumors.

References

  1. June, C. H. & Sadelain, M. N. Engl. J. Med. 379, 64–73 (2018).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Sterner, R. C. & Sterner, R. M. Blood Cancer J 11, 1–11 (2021).

    Article  Google Scholar 

  3. Mackensen, A. et al. Nat. Med. https://doi.org/10.1038/s41591-023-02612-0 (2023).

    Article  PubMed  Google Scholar 

  4. Hewitt, K. J., Agarwal, R. & Morin, P. J. BMC Cancer 6, 186 (2006).

    Article  PubMed  PubMed Central  Google Scholar 

  5. Zhang, C. et al. Front. Cell Dev. Biol. 9, 726656 (2021).

    Article  PubMed  PubMed Central  Google Scholar 

  6. Ushiku, T., Shinozaki-Ushiku, A., Maeda, D., Morita, S. & Fukayama, M. Histopathology 61, 1043–1056 (2012).

    Article  PubMed  Google Scholar 

  7. Veenstra, C. M. & Vaughn, D. J. Hematol. Oncol. Clin. North Am. 25, 577–591 (2011).

    Article  PubMed  Google Scholar 

  8. Mateus-Tique, J. & Brown, B. Nat. Rev. Immunol. 23, 7 (2023).

    Article  CAS  PubMed  Google Scholar 

  9. Kranz, L. M. et al. Nature 534, 396–401 (2016).

    Article  PubMed  Google Scholar 

  10. Reinhard, K. et al. Science 367, 446–453 (2020).

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medical Oncology & Experimental Therapeutics; City of Hope Comprehensive Cancer Center, Duarte, CA, USA

    Alex Chehrazi-Raffle & Sumanta K. Pal

  2. Department of Hematology & Hematopoietic Cell Transplantation; City of Hope Comprehensive Cancer Center, Duarte, CA, USA

    Lihua E. Budde

Authors
  1. Alex Chehrazi-Raffle
    View author publications

    Search author on:PubMed Google Scholar

  2. Lihua E. Budde
    View author publications

    Search author on:PubMed Google Scholar

  3. Sumanta K. Pal
    View author publications

    Search author on:PubMed Google Scholar

Corresponding author

Correspondence to Sumanta K. Pal.

Ethics declarations

Competing interests

A.C.-R. reports consulting roles with Aveo, Exelixis and Tempus Labs. S.K.P. reports consulting roles in Genentech, Aveo, Eisai, Roche, Pfizer, Novartis, Exelixis, Ipsen, BMS and Astellas. L.E.B. declares no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Chehrazi-Raffle, A., Budde, L.E. & Pal, S.K. Boosting CAR T cells with anti-tumor mRNA vaccines. Nat Med 29, 2711–2712 (2023). https://doi.org/10.1038/s41591-023-02623-x

Download citation

  • Published:

  • Version of record:

  • Issue date:

  • DOI: https://doi.org/10.1038/s41591-023-02623-x

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing